Vascular endothelial growth factor and vascular permeability changes in human diabetic retinopathy

Investigative Ophthalmology and Visual Science

Volumn 38, Issue 13, 1997, Pages 2729-2741

  Mathews, Michaela Kunz ^a   Merges, Carol ^a   McLeod, D Scott ^a   Lutty, Gerald A ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

Diabetic retinopathy; Heparan sulfate proteoglycan; Immunohistochemistry; Vascular endothelial growth factor; Vascular permeability

Indexed keywords

APYRASE; COLLAGEN TYPE 4; HEPARIN BINDING PROTEIN; PROTEOHEPARAN SULFATE; VASCULOTROPIN RECEPTOR; VON WILLEBRAND FACTOR;

ADULT; AGED; ANTIBODY DETECTION; ARTICLE; BLOOD VESSEL PERMEABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC RETINOPATHY; HISTOCHEMISTRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREACTIVITY; PRIORITY JOURNAL; RETINA BLOOD FLOW; VASCULAR ENDOTHELIUM;

ADULT; AGED; AGED, 80 AND OVER; APYRASE; CAPILLARY PERMEABILITY; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; ENDOTHELIAL GROWTH FACTORS; HEPARAN SULFATE PROTEOGLYCANS; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPHOKINES; MIDDLE AGED; RETINAL VESSELS; SERUM ALBUMIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0031456416     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Michaelson IC. The mode of development of the vascular system of the retina, with some observations on its significance for certain retinal diseases. Trans Ophthalmol Soc UK. 1948;68:137-180.
2. Keck PJ, Hauser SD, Krivi G, et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science. 1989;246:1309-1312.
3. Ferrara N, Houck KA, Jakeman LB, Winer J, Leung DW. The vascular endothelial growth factor family of polypeptides. J Cell Biochem. 1991;47:211-218.
4. Houck KA, Ferrara N, Winer J, Cachianes G, Li B, Leung DW. The vascular endothelial growth factor family: Identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol. 1991;5:1806-1814.
5. Plouet J, Moukadiri H. Characterization of the receptor to vasculotropin on bovine adrenal cortex-derived capillary endothelial cells. J Biol Chem. 1990;265: 22071-22074.
6. Gitay-Goren H, Soker S, Vlodavski I, Neufeld G. The binding of vascular endothelial growth factor to its receptors is dependent on cell surface-associated heparin-like molecules. J Biol Chem. 1992;267(9) :6093-6098.
7. Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun. 1989;161:851-858.
8. Adamis AP, Shima DT, Yeo KT, et al. Synthesis and secretion of vascular permeability factor/vascular endothelial growth factor by human retinal pigment epithelial cells. Biochem Biophys Res Commun. 1993;193: 631-638.
9. Aiello LP, Northrup JM, Keyt BA, Takagi H, Iwamoto MA. Hypoxic regulation of vascular endothelial growth factor in retinal cells. Arch Ophthalmol. 1995; 113:1538-1544.
10. Simorre-Pinatel V, Guerrin M, Chollet P, et al. Vasculotropin-VEGF stimulates retinal capillary endothelial cells through an autocrine pathway. Invest Ophthalmol Vis Sci. 1994;35:3393-3400.
11. Takagi H, King GL, Robinson GS, Ferrara N, Aiello LP. Adenosine mediates hypoxic induction of vascular endothelial growth factor in retinal pericytes and endothelial cells. Invest Ophthalmol Vis Sci. 1996;37:2165-2176.
12. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature. 1992;359:843-845.
13. Shima DT, Deutsch U, D'Amore P. Hypoxic induction of vascular endothelial growth factor (VEGF) in human epithelial cells is mediated by increases in mRNA stability. FEBS Letters. 1995;370:203-208.
14. Pe'er J, Shweiki D, Itin A, Hemo I, Gnessin H, Keshet E. Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases. Lab Invest. 1994; 72(6):638-645.
15. Shima DT, Gougos A, Miller JW, et al. Cloning and mRNA expression of VEGF in ischemic retinas of Macaca fasicularis. Invest Ophthalmol Vis Sci. 1996;37: 1334-1340.
16. Miller JW, Adamis AP, Shima DT, et al. Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am J Pathol. 1994;145: 575-584.
17. Pierce EA, Avery RL, Foley ED, Aiello LP, Smith LEH. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. PNAS. 1995;92:905-909.
18. Stone J, Itin A, Alon T, et al. Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia. J Neurosci. 1995;15:4738-4747.
19. Favard C, Moukadiri H, Dorey C, Praloran V, Plouet J. Purification and biological properties of vasculotropin, a new angiogenic cytokine. Biol Cell. 1991;73: 1-6.
20. Murata T, Ishibashi T, Ahmad K, Hata Y, Yoshikawa H, Inomata H. Vascular endothelial growth factor plays a role in hyperpermeability of diabetic retinal vessels. Ophthalmic Res. 1995;27:48-52.
21. Dvorak HF, Sioussat TM, Brown LF, et al. Distribution of vascular permeability factor (vascular endothelial growth factor) in tumors: Concentration in tumor blood vessels. J Exp Med. 1991;174:1275-1278.
22. Vinores SA, Kuechle M, Mahlow J, Chiu C, Green WR, Campochiaro P. Blood-ocular barrier breakdown in eyes with ocular melanoma. Am J Path. 1995;147(5): 1289-1297.
23. Brown LF, Olbricht SM, Berse B, et al. Overexpression of vascular permeability factor (VEGF/VPF) and its endothelial cell receptors in delayed hypersensitivity skin reactions. J Immunol. 1995;154:2801-2807.
24. Lutty GA, McLeod DS, Merges C, Diggs A, Plouet J. Localization of VEGF in human retina and choroid. Arch Ophthalmol. 1996;114:971-977.
25. Adamis AP, Miller JW, Bernai M-T, et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol. 1994;118:445-450.
26. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331(22):1480-1487.
27. Malecaze F, Clamens S, Simorre-Pinatel V, et al. Detection of vascular endothelial growth factor messenger RNA and vascular endothelial growth factor-like activity in proliferative diabetic retinopathy. Arch Ophthalmol. 1994;112:1476-1482.
28. Lutty GA, McLeod DS. A new technique for visualization of the human retinal vasculature. Arch Ophthalmol. 1992;110:267-276.
29. Lutty G, Ikeda K, Chandler C, McLeod DS. Immunohistochemical localization of transforming growth factor-B in human photoreceptors. Curr Eye Res. 1991;10: 61-74.
30. Lutty GA, Merges C, Threlkeld AB, Crone S, McLeod DS. Heterogeneity in localization of isoforms of TGF-β in human retina, vitreous, and choroid. Invest Ophthalmol Vis Sci. 1993;34:477-487.
31. Early Treatment Diabetic Retinopathy Study Research Group. Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS Report Number 12. Ophthalmology. 1991;98:823-833.
32. Kohner EM, Dollery CT. Diabetic retinopathy. In: Keen H, Jarrett J, eds. Complications of Diabetes. London: Edward Arnold; 1975:7-98.
33. Wolf S, Arend O, Schulte K, Ittel TH, Reim M. Quantification of retinal capillary density and flow velocity in patients with essential hypertension. Hypertension. 1994;23:464-467.
34. Cunha-Vaz JG, Abreu JF, Campos AJ, Figo GM. Early breakdown of the blood-retinal barrier in diabetes. Br J Ophthalmol. 1975;59:649-656.
35. Senger DD, Perruzzi CA, Feder J, Dvorak HF. A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. Cancer Res. 1986;46:5629-5632.
36. Vinores SA, Gadegbeku C, Campochiaro PA, Green WR. Immunohistochemical localization of blood-retinal barrier breakdown in human diabetics. Am J Pathol. 1989;134:231-235.
37. Saksela O, Rifkin DB. Release of basic fibroblast growth factor-heparan sulfate complexes from endothelial cells by plasminogen activator-mediated proteolytic activity. J Cell Biol 1990;110:767-775.
38. Hanneken A, de Juan E, Lutty G, et al. Altered distribution of basic fibroblast growth factor in diabetic retinopathy. Arch Ophthalmol. 1991;109:1005-1011.
39. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Path. 1995;146(5):1029-1039.
40. Amin RH, Frank RN, Kennedy A, Elliot D, Puklin JE, Abrams GW. Vascular endothelial growth factor is present in glial cells of the retina and optic nerve of human subjects with nonproliferative diabetic retinopathy. Invest Ophthalmol Vis Sci. 1997;38:36-47.
41. Tolentino MJ, Miller JW, Gragoudas ES, et al. Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. Ophthalmology. 1996;103:1820-1828.